Research ExplorerJournalsLANCET HAEMATOL

LANCET HAEMATOL

Bibliographical data

ISSNs2352-3026
Electronic ISSN 2352-3026

Publications

High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
Schorb, E., Isbell, L. K., Kerkhoff, A., Mathas, S., Braulke, F., Egerer, G., Röth, A., Schliffke, S., Borchmann, P., Brunnberg, U., Kroschinsky, F., Möhle, R., Rank, A., Wellnitz, D., Kasenda, B., Pospiech, L., Wendler, J., Scherer, F., Deckert, M., Henkes, E., von Gottberg, P., Gmehlin, D., Backenstraß, M., Jensch, A., Burger-Martin, E., Grishina, O., Fricker, H., Malenica, N., Orbán, A., Duyster, J., Ihorst, G., Finke, J. & Illerhaus, G., 03.2024, In: LANCET HAEMATOL. 11, 3, p. e196-e205

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Mai, E. K., Goldschmid, H., Miah, K., Bertsch, U., Besemer, B., Hänel, M., Krzykalla, J., Fenk, R., Schlenzka, J., Munder, M., Dürig, J., Blau, I. W., Huhn, S., Hose, D., Jauch, A., Kunz, C., Mann, C., Weinhold, N., Scheid, C., Schroers, R., von Metzler, I., Schieferdecker, A., Thomalla, J., Reimer, P., Mahlberg, R., Graeven, U., Kremers, S., Martens, U. M., Kunz, C., Hensel, M., Benner, A., Seidel-Glätzer, A., Weisel, K. C., Raab, M. S., Salwender, H. J. & German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators, 02.2024, In: LANCET HAEMATOL. 11, 2, p. e101-e113

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Penack, O., Marchetti, M., Aljurf, M., Arat, M., Bonifazi, F., Duarte, R. F., Giebel, S., Greinix, H., Hazenberg, M. D., Kröger, N., Mielke, S., Mohty, M., Nagler, A., Passweg, J., Patriarca, F., Ruutu, T., Schoemans, H., Solano, C., Vrhovac, R., Wolff, D., Zeiser, R., Sureda, A. & Peric, Z., 02.2024, In: LANCET HAEMATOL. 11, 2, p. e147-e159 13 p.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study
Tiede, A., Hart, C., Knöbl, P., Greil, R., Oldenburg, J., Sachs, U. J., Miesbach, W., Pfrepper, C., Trautmann-Grill, K., Holstein, K., Pilch, J., Möhnle, P., Schindler, C., Weigt, C., Schipp, D., May, M., Dobbelstein, C., Pelzer, F. J., Werwitzke, S. & Klamroth, R., 11.2023, In: LANCET HAEMATOL. 10, 11, p. e913-e921

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., Bright, S., Currie, B., Perera, S., Boyle, J., Roy-Ghanta, S., Opalinska, J. & Weisel, K., 10.2023, In: LANCET HAEMATOL. 10, 10, p. e801-e812

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians
Gurnari, C., Spadea, M., Muratori, R., Jimenez, V., Radici, V., Torrado, S., Desai, N., Ropero, J., Muhsen, I. N., Ibrahimova, A., Du Toit, J., Hendricks, C. L., Gagelmann, N. & Horga, C., 07.2023, In: LANCET HAEMATOL. 10, 7, p. e492-e494

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial
Döhner, H., Weber, D., Krzykalla, J., Fiedler, W., Kühn, M. W. M., Schroeder, T., Mayer, K., Lübbert, M., Wattad, M., Götze, K., Fransecky, L., Koller, E., Wulf, G., Schleicher, J., Ringhoffer, M., Greil, R., Hertenstein, B., Krauter, J., Martens, U. M., Nachbaur, D., Samra, M. A., Machherndl-Spandl, S., Basara, N., Leis, C., Schrade, A., Kapp-Schwoerer, S., Cocciardi, S., Bullinger, L., Thol, F., Heuser, M., Paschka, P., Gaidzik, V. I., Saadati, M., Benner, A., Schlenk, R. F., Döhner, K., Ganser, A. & German–Austrian AML Study Group, 07.2023, In: LANCET HAEMATOL. 10, 7, p. e495-e509

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Long-term sequelae after immunotherapeutic approaches in haematological malignancies-what do we know?
Escherich, G. & Hough, R., 06.2023, In: LANCET HAEMATOL. 10, 6, p. e395-e396

Research output: SCORING: Contribution to journal › Comment/debate › Research

Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma
Beishuizen, A., Mellgren, K., Andrés, M., Auperin, A., Bacon, C. M., Bomken, S., Burke, G. A. A., Burkhardt, B., Brugieres, L., Chiang, A. K. S., Damm-Welk, C., d'Amore, E., Horibe, K., Kabickova, E., Khanam, T., Kontny, U., Klapper, W., Lamant, L., Le Deley, M-C., Loeffen, J., Macintyre, E., Mann, G., Meyer-Wentrup, F., Michgehl, U., Minard-Colin, V., Mussolin, L., Oschlies, I., Patte, C., Pillon, M., Reiter, A., Rigaud, C., Roncery, L., Salaverria, I., Simonitsch-Klupp, I., Uyttebroeck, A., Verdu-Amoros, J., Williams, D., Woessmann, W., Wotherspoon, A., Wrobel, G., Zimmermann, M., Attarbaschi, A., Turner, S. D. & European Intergroup for Childhood Non-Hodgkin Lymphoma, 03.2023, In: LANCET HAEMATOL. 10, 3, p. e213-e224 12 p.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?
Gagelmann, N. & Brudno, J., 02.2023, In: LANCET HAEMATOL. 10, 2, p. e82-e83

Research output: SCORING: Contribution to journal › Comment/debate › Research

View all (32)